145 related articles for article (PubMed ID: 35446267)
21. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
Corrigan PA; Beaulieu C; Patel RB; Lowe DK
Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
[TBL] [Abstract][Full Text] [Related]
22. Panniculitis in a patient with pathologic complete response to talimogene laherparepvec treatment for recurrent, in-transit melanoma.
Long TH; Shinohara MM; Argenyi ZB; Thompson JA; Gardner JM
J Cutan Pathol; 2018 Nov; 45(11):864-868. PubMed ID: 30054925
[TBL] [Abstract][Full Text] [Related]
23. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.
Andtbacka RHI; Amatruda T; Nemunaitis J; Zager JS; Walker J; Chesney JA; Liu K; Hsu CP; Pickett CA; Mehnert JM
EBioMedicine; 2019 Sep; 47():89-97. PubMed ID: 31409575
[TBL] [Abstract][Full Text] [Related]
24. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience.
Carr MJ; Sun J; DePalo D; Rothermel LD; Song Y; Straker RJ; Baecher K; Louie RJ; Stahlie EHA; Wright GP; Naqvi SMH; Kim Y; Sarnaik AA; Karakousis GC; Lowe MC; Delman KA; van Akkooi ACJ; Ollila DW; Collichio F; Zager JS
Ann Surg Oncol; 2022 Feb; 29(2):791-801. PubMed ID: 34648098
[TBL] [Abstract][Full Text] [Related]
25. Intratumoral administration of CD1c (BDCA-1)
Schwarze JK; Tijtgat J; Awada G; Cras L; Vasaturo A; Bagnall C; Forsyth R; Dufait I; Tuyaerts S; Van Riet I; Neyns B
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113895
[TBL] [Abstract][Full Text] [Related]
26. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
Garnock-Jones KP
BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
[TBL] [Abstract][Full Text] [Related]
27. Dermoscopy as response evaluation tool for cutaneous malignant melanoma metastases treated with Talimogene Laherparepvec: a prospective feasibility study.
Stahlie EHA; van Akkooi ACJ; Plasmeijer E
J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):2373-2378. PubMed ID: 35920755
[TBL] [Abstract][Full Text] [Related]
28. An evaluation of talimogene laherparepvec for the treatment of melanoma.
Broman KK; Zager JS
Expert Opin Biol Ther; 2020 Jan; 20(1):9-14. PubMed ID: 31690129
[No Abstract] [Full Text] [Related]
29. Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report.
Chitnis SD; Seim NB; Kendra K
J Med Case Rep; 2024 May; 18(1):257. PubMed ID: 38778387
[TBL] [Abstract][Full Text] [Related]
30. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Bagust A; Boland A; Beale S; Richardson M; Krishan A; Stainthorpe A; Abdulla A; Kotas E; Banks L; Payne M
Pharmacoeconomics; 2017 Oct; 35(10):1035-1046. PubMed ID: 28316007
[TBL] [Abstract][Full Text] [Related]
31. Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment.
Park SY; Green AR; Hadi R; Doolittle-Amieva C; Gardner J; Moshiri AS
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36307152
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial.
Dummer R; Gyorki DE; Hyngstrom J; Berger AC; Conry R; Demidov L; Sharma A; Treichel SA; Radcliffe H; Gorski KS; Anderson A; Chan E; Faries M; Ross MI
Nat Med; 2021 Oct; 27(10):1789-1796. PubMed ID: 34608333
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
[TBL] [Abstract][Full Text] [Related]
34. Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Ressler JM; Karasek M; Koch L; Silmbrod R; Mangana J; Latifyan S; Aedo-Lopez V; Kehrer H; Weihsengruber F; Koelblinger P; Posch C; Kofler J; Michielin O; Richtig E; Hafner C; Hoeller C
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608376
[TBL] [Abstract][Full Text] [Related]
35. Complete response to talimogene laherparepvec in a primary acral lentiginous melanoma.
Franke V; Smeets PMG; van der Wal JE; van Akkooi ACJ
Melanoma Res; 2020 Dec; 30(6):548-551. PubMed ID: 32516238
[TBL] [Abstract][Full Text] [Related]
36. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
Grigg C; Blake Z; Gartrell R; Sacher A; Taback B; Saenger Y
Semin Oncol; 2016 Dec; 43(6):638-646. PubMed ID: 28061981
[TBL] [Abstract][Full Text] [Related]
37. Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma.
Fazel M; AlRawashdh N; Alamer A; Curiel-Lewandrowski C; Abraham I
Expert Opin Biol Ther; 2021 Dec; 21(12):1647-1653. PubMed ID: 34693839
[TBL] [Abstract][Full Text] [Related]
38. How We Do It: Administration Guide for Intralesional Immunotherapy With Talimogene Laherparepvec (T-VEC) for Advanced Melanoma.
Queen D; Samie FH; Zeitouni NC
Dermatol Surg; 2020 Nov; 46(11):1455-1457. PubMed ID: 31403542
[No Abstract] [Full Text] [Related]
39. Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec.
Audrey-Bayan C; Trager MH; Gartrell-Corrado RD; Rizk EM; Pradhan J; Silverman AM; Lopez A; Marks DK; Niedt G; Geskin LJ; Saenger YM
Melanoma Res; 2020 Aug; 30(4):410-415. PubMed ID: 32379409
[TBL] [Abstract][Full Text] [Related]
40. Ultrasound-guided Intralesional Injection of Talimogene laherparepvec (Imlygic) for Advanced Melanoma: Technical Note on a Preliminary Experience.
Burke LMB; Yu H; Burke K; Gwynn M; Louie RJ; Ollila DW; Rn PL; Collichio F
Cardiovasc Intervent Radiol; 2021 May; 44(5):801-806. PubMed ID: 33447922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]